Brokerages Set DaVita Inc. (NYSE:DVA) Target Price at $161.80

Shares of DaVita Inc. (NYSE:DVA) have been given an average recommendation of “Hold” by the five analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $161.80.

DVA has been the subject of several analyst reports. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial increased their target price on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th.

DaVita Price Performance

Shares of NYSE:DVA opened at $166.28 on Wednesday. The firm’s 50 day simple moving average is $157.11 and its two-hundred day simple moving average is $152.92. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a market capitalization of $13.63 billion, a P/E ratio of 17.94, a P/E/G ratio of 0.75 and a beta of 0.92. DaVita has a 1-year low of $103.40 and a 1-year high of $169.51.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the company earned $2.85 EPS. The business’s revenue was up 4.6% on a year-over-year basis. Research analysts expect that DaVita will post 9.71 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several institutional investors and hedge funds have recently bought and sold shares of DVA. Transcendent Capital Group LLC purchased a new stake in shares of DaVita during the third quarter valued at $25,000. Blue Trust Inc. boosted its holdings in DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after buying an additional 119 shares in the last quarter. Quarry LP purchased a new position in shares of DaVita in the 3rd quarter valued at about $60,000. Point72 Hong Kong Ltd acquired a new stake in DaVita in the 2nd quarter valued at $68,000. Finally, Versant Capital Management Inc increased its stake in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after purchasing an additional 169 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.